Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4

Archives of Neurology

Volumn 57, Issue 6, 2000, Pages 869-874

  Olichney, Jolin M ^a,b,c   Hansen, Lawrence A ^a   Hofstetter, C Richard ^a   Lee, Jae Hong ^d   Katzman, Robert ^a   Thal, Leon J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; VASCULAR AMYLOIDOSIS;

EID: 0034099649     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.6.869     Document Type: Article

References (52)

1. Molsa PK, Paljarvi L, Rinne JD, et al. Validity of clinical diagnosis in dementia. J Neurol Neurosurg Psychiatry. 1985;48:1085-1090.
2. Malamud N. Neuropathology of organic brain syndromes associated with aging. In: Gaitz CM, ed. Aging and the Brain. New York. NY: Plenum Publishing Corp; 1972:63-87.
3. Tomlinson BE, Blessed S, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205-242.
4. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18:311-324.
5. Glenner GG, Henry JH, Fujihara S. Congophillic angiopathy in the pathogenesis of Alzheimer's degeneration. Ann Pathol. 1981;1:120-129.
6. Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology. 1975;25:120-126.
7. Olichney JM, Hansen L, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol. 1995;52:702-708.
8. Olichney JM, Ellis RJ, Katzman R, Sabbagh MN, Hansen L. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer's disease. Ann N Y Acad Sci. 1997;826:493-497.
9. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E-∈4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-259.
10. Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-∈4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol. 1996;148:2083-2095.
11. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E ∈4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology. 1996;47:190-196.
12. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160-165.
13. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272:1666-1671.
14. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
15. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
16. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097-1105.
17. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
19. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 1994:51:888-895.
20. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
21. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
22. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;31:545-548.
23. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele epsillon 4 is over-represented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 1994;44:1950-1951.
24. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983;3:310-315.
25. Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol. 1985;18:54-59.
26. Okazaki H, Reagan TJ, Campbell PJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc. 1979;54:22-31.
27. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP. The clinical spectrum of cerebral amyloid angiopathy. Neurology. 1993;43:2073-2079.
28. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP. Cerebral amyloid angiopathy without and with cerebral hemorrhages:a comparative histological study. Ann Neurol. 1991;30:637-649.
29. Nicoll JAR, Burnett C, Love S, et al. High frequency of apolipoprotein E 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;4:716-721.
30. Mandybur TI. Cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 1986;45: 79-90.
31. Pedro-Botet J, Senti M, Nogues X, et al. Lipoprotein and apoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride rich lipoproteins, and apolipoprotein E polymorphism Stroke. 1992:23:1556-1562.
32. Basun H, Corder EH, Guo Z, et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke. 1996;27:1310-1315.
33. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24:661-664.
34. Shimano H, Ishibashi S, Murase T, et al. Plasma apolipoproteins in patients with multi-infarct dementia. Atherosclerosis. 1989;79:257-260.
35. Frisoni GB, Calabresi L, Geroldi C, Bianchetti A. Apolipoprotein E-∈4 allele in Alzheimer's disease and vascular dementia. Dementia. 1994:5:240-242.
36. Ji Y, Urakami K, Adachi Y, Maeda M, Isoe K, Nakashima K, Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease. Dement Geriatr Cogn Disord. 1998:9:243-245.
37. Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease and vascular dementia. J Neurol Neurosurg Psychiatry. 1994;57:1414-1416.
38. Palumbo B, Parnetti L, Nocentini G, Cardinali L. Apolipoprotein E genotype in normal aging, age-associated memory impairment. Alzheimer's disease, and vascular dementia patients. Neurosci Lett. 1997;231:59-61.
39. Betard C, Robitaille Y, Gee M, et al. Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuroreport. 1994;5:1893-1896.
40. Olichney JM, Sabbagh MN, Hofstetter CR, et al. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology. 1997;49:76-81.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
42. Farrar, LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: a meta-analysis. APOE and Alzheimer's disease meta analysis consortium. JAMA 1997; 278:1349-1356.
43. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of incidence and distribution in Hisayama, Japan. Stroke. 1992;23:1556-1562.
44. Weller, RO, Masses, A, Newman, TA, Hutchings, M, Kuo, YM, Roher, AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol. 1998;153: 725-33.
45. Urmoneit, B, Prikulis, I, Wihl, G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest. 1997;77:157-166.
46. Perry RH, McKeith IG, Perry EK. Dementia With Lewy Bodies: Clinical, Pathological. and Treatment Issues. New York. NY: Cambridge Press; 1996.
47. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci. 1990;95:239-258.
48. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168-171.
49. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease. Lab Invest. 1998;78:461-469.
50. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun. 1995; 213:96-103.
51. Van Nostrand WE, Davis-Salinas J, Saporito-Irwin SM. Amyloid β-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann N Y Acad Sci. 1996;777:297-302.
52. Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues. Nature Med. 1995; 1:138-142.